ASH CONFERENCE REVIEW
During this year's American Society of Hematology (ASH) annual meeting, national experts will tackle the hottest topics in hematology. Here's your conference insider. |
Top Stories |
|
Myeloma combination treatments get the once-over by leading cancer expert. Details |
|
As researchers uncover biomarkers for cancer subtypes, collaboration between researchers, pathologists and physicians will improve accurate diagnosis of lymphoma subtypes. Read more. |
|
Next-generation gene sequencing and other advanced technologies for personalized medicine may soon identify biomarkers that will improve treatment response, long-term toxicity risks for childhood cancer patients. Read more. |
|
Acute myeloid leukemia’s genetic complexity raises concerns about long-term prospects of single mutation-targeting agents. Details. |
|
DISCLAIMER:
This information has been independently developed and provided by the editors of Managed Healthcare Executive. The Managed Healthcare Executive brand and this e-newsletter are in no way affiliated with the conference event or parent organization. The sponsors do not endorse and are not responsible for the accuracy of the content or for practices or standards of non-sponsor sources. These articles may discuss regimens that have not been approved by the FDA. For full prescribing information including indications, contraindications, warnings, precautions, and adverse experiences, please see the appropriate manufacturer's product circular. |
|
